Pfizer’s Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move — Here’s Why

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 24 May, 2016 by The TZ Newswire Staff

Pfizer’s Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move — Here’s Why

Merger Acquisition Handshake Getty

After an unexpected breakup in April that saw the pending megamerger between Pfizer (NYSE: PFE) and Allergan fall by the wayside, Pfizer has found its new target.

See also
- Next Article Who Is Nike’s Favorite Customer?
- Previous Article Nokia Corp.’s Return to Mobile Is Spot-On
Editorial Calender

May 2016

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30 31

« Apr Jun »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 24 May, 2016 by The TZ Newswire Staff

Pfizer’s Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move — Here’s Why

See also

Editorial Calender

Recent Tags